This study is the first dedicated trial of endocrine therapy (ET) ± a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in premenopausal patients (pts) with hormone receptor–positive (HR+)/HER2− ABC. Hear Sara A. Hurvitz present for the first time that a CDK4/6 inhibitor or any targeted agent + endocrine therapi ET has demonstrated significantly longer OS vs ET ...

In the COLET study Adam Brufsky et al investigated the efficacy and safety of Atezolizumab + cobimetinib + paclitaxel/nab-paclitaxel as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (mTNBC). This combination may target multiple cancer immune escape mechanisms simultaneously. Hear Adam Brufsky present the ...

The message from Monica Bertagnolli, President of ASCO, is clear. The theme for this year ASCO congress are Cary for every patients – learning from every patients. Hear Monica Bertagnolli expectations to this ASCO ...